Allgemeine Abschätzung des kardiovaskulären Risikos

Zusammenfassung

Validierte Scores zur Bestimmung des kardiovaskulären Risikos erlauben es, die Individuen zu identifizieren, die von präventiven Interventionen am meisten profitieren. Daneben verdeutlichen sie auf individueller Basis die Folgen ungesunden Lebensstils und die Risikoreduktion durch zielgerichtete Anpassung (z.B. LDL-C-Reduktion). Scores sind damit ein wichtiges Instrument zur Motivation von Patienten, ihr Risikoprofil zu verbessern.

Abstract

The assessment of individual cardiovascular disease risk (CVD) is essential for a cost-effective prevention of cardiovascular morbidity and mortality. While almost half of the population have a very low CVD risk approximately 1/5^th of the population have a CVD risk >20% over the next 10 years.

Modern risk scores like the ESC-SCORE2 help to identify those in need of intensified preventive efforts based on basic risk factors like smoking, systolic blood pressure, total cholesterol, age, and sex. According to current ESC-guidelines all men >45 years and all women >55 years should be assessed with SCORE2, which is the best calibrated and validated scoring system for Europe.

The calculation of total cardiovascular risk also permits to calculate an individual heart-age, which makes it easier for the individual patient to understand his own risk profile. Most current risk estimation systems can be accessed online under u-prevent.com/calculators.

Kernaussagen

• Gerade in Anbetracht des aktuellen demografischen Wandels wird die kardiovaskuläre Prävention immer wichtiger.

• Moderne Scoring-Instrumente wie der ESC-SCORE2 helfen, frühzeitig Menschen zu identifizieren, die ein hohes Risiko aufweisen, eine kardiovaskuläre Erkrankung zu entwickeln.

• Nach den aktuellen ESC-Präventionsleitlinien sollten alle Männer ab dem 45. Lebensjahr und alle Frauen ab dem 55. Lebensjahr ein Risiko-Assessment mit einem validierten Score erhalten.

• Der ESC-SCORE2 ist für die europäischen Länder am besten validiert und kann daher für diesen Zweck uneingeschränkt empfohlen werden.

Schlüsselwörter

Risiko - kardiovaskulär - Gesamtrisiko - Risikoabschätzung - Primärprävention - ESC-SCORE2

Keywords

risk - cardiovascular - total risk - primary prevention - ESC-SCORE2

Publikationsverlauf

Artikel online veröffentlicht:
09. September 2024

• Literatur

• 1 Dalen JE, Alpert JS, Goldberg RJ. et al. The epidemic of the 20(th) century: coronary heart disease. Am J Med 2014; 127: 807-812
• 2 Mahmood SS, Levy D, Vasan RS. et al. The Framingham Heart Study and the epidemiolo-gy of cardiovascular disease: a historical perspective. Lancet Lond Engl 2014; 383: 999-1008
• 3 Meigs JB, D’Agostino RB, Wilson PW. et al. Risk variable clus-tering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46: 1594-1600
• 4 Anderson KM, Wilson PW, Odell PM. et al. An updated coronary risk profile. A state-ment for health professionals. Circulation 1991; 83: 356-362
• 5 Wilson PW, D’Agostino RB, Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847
• 6 D’Agostino RB, Vasan RS, Pencina MJ. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753
• 7 Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J Clin Res Ed 1981; 282: 1847-1851
• 8 Manuel DG, Lim J, Tanuseputro P. et al. Revisit-ing Rose: strategies for reducing coronary heart disease. BMJ 2006; 332: 659-662
• 9 World Health Organization. Cardiovascular disease prevention and control: translating evi-dence into action. Genf; WHO. 2005 Zugriff am 13. Mai 2023 unter: https://apps.who.int/iris/bitstream/handle/10665/43235/9241593253_eng.pdf;jsessionid=7FF2AFF9CA9C2F35079C832CD6CBF3E1?sequence=1
• 10 Cooney MT, Dudina A, D’Agostino R. et al. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?. Circulation 2010; 122: 300-310
• 11 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardio-vascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337
• 12 SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42: 2439-2454
• 13 Lloyd-Jones DM, Leip EP, Larson MG. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113: 791-798
• 14 Reuter S, Reiermann S, Malyar V. et al. A Comparison of Different Algorithms for the Assessment of Cardiovascular Risk in Patients at Waiting List for Kidney Transplantation. PloS One 2016; 11: e0161927
• 15 Artigao-Rodenas LM, Carbayo-Herencia JA, Divisón-Garrote JA. et al. Framingham risk score for prediction of cardiovascular dis-eases: a population-based study from southern Europe. PloS One 2013; 8: e73529
• 16 No authors listed. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–1503.
• 17 Pyörälä K, De Backer G, Graham I. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331
• 18 Conroy RM, Pyörälä K, Fitzgerald AP. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
• 19 D’Agostino RB, Grundy S, Sullivan LM. et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187
• 20 Pyörälä K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J 2000; 21: 348-350
• 21 Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365-370
• 22 D’Agostino RB, Russell MW, Huse DM. et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272-281
• 23 Assmann G, Cullen P, Schulte H. et al. Response to Conroy et al. SCORE Project. Eur Heart J 2003; 24 (24) 2070-2071
• 24 Piepoli MF, Hoes AW, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381
• 25 Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG. Statin Eligibility for Primary Preven-tion of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. JAMA Cardiol 2022; 7 (08) 836-843
• 26 Gielen S, Wienbergen H, Reibis R. et al. Kommentar zu den neuen Leitlinien (2021) der Europäischen Gesellschaft für Kardiologie (ESC) zur kardiovaskulären Prävention. Kardiologie 2022; 16 (06) 439-454
• 27 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
• 28 Rossello X, Dorresteijn JA, Janssen A. et al. Risk prediction tools in cardiovascular dis-ease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Profes-sions (ACNAP). Eur Heart J Acute Cardiovasc Care 2020; 9: 522-532
• 29 Kengne AP. The ADVANCE cardiovascular risk model and current strategies for cardiovascu-lar disease risk evaluation in people with diabetes. Cardiovasc J Afr 2013; 24: 376-381
• 30 JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart Br Card Soc 2014; 100: ii1-ii67
• 31 Stam-Slob MC, Visseren FLJ, Wouter Jukema J. et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elder-ly patients. Clin Res Cardiol Off J Ger Card Soc 2017; 106: 58-68
• 32 Kleipool EE, Dorresteijn JA, Smulders YM. et al. Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach. Heart Br Card Soc 2020; 106: 261-266
• 33 Hajifathalian K, Ueda P, Lu Y. et al. A novel risk score to pre-dict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015; 3: 339-355
• 34 Gielen S, Koenig W, Landmesser U. et al. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (Hrsg.). ESC Pocket Guidelines. Prävention von Herz-Kreislauf-Erkrankungen. Version 2021. Grünwald: Bruckmeier. 2022 Zugriff am 13. Mai 2023 unter: https://leitlinien.dgk.org/2022/pocket-leitlinie-praevention-von-herz-kreislauf-erkrankungen-version-2021/
• 35 Riggs DW, Yeager RA, Bhatnagar A. Defining the Human Envirome: An Omics Approach for Assessing the Environmental Risk of Cardiovascular Disease. Circ Res 2018; 122: 1259-1275
• 36 Münzel T, Miller MR, Sørensen M. et al. Reduction of envi-ronmental pollutants for prevention of cardiovascular disease: it’s time to act. Eur Heart J 2020; 41: 3989-3997
• 37 Lelieveld J, Münzel T. Air pollution, chronic smoking, and mortality. Eur Heart J 2019; 40: 3204
• 38 Davies HW, Teschke K, Kennedy SM. et al. Occupational exposure to noise and mortality from acute myocardial infarction. Epidemiol Camb Mass 2005; 16: 25-32